SciLogica develops the Elucido™ platform, which utilizes light-based technology for continuous, real-time measurement of blood analytes. This capability enables medical teams to make timely, accurate decisions that improve patient outcomes and reduce hospital costs.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for measuring blood analytes often rely on intermittent sampling and laboratory analysis, leading to delays in obtaining critical information about a patient's condition. This delay can hinder timely clinical decision-making and potentially impact patient outcomes, particularly in critical care settings.
Solution
SciLogica's Elucido™ platform offers continuous, real-time measurement of blood analytes using light-based technology. By integrating directly with extracorporeal blood treatment systems, Elucido™ provides medical teams with immediate access to accurate data, enabling faster and more informed decisions. The platform aims to improve patient outcomes and reduce hospital costs by providing a continuous stream of critical blood analyte information. The Elucido™ platform allows for semi-integrated and fully integrated solutions to be developed.
Target Audience
The primary target audience includes medical teams in hospitals and clinics, particularly those involved in critical care and extracorporeal blood treatment.
Features
- Continuous monitoring of blood analytes in real-time
- Light-based technology for accurate measurements
- Integration with extracorporeal blood treatment systems
- Display of historical trend data
- Customizable platform for integrated solutions